Human gene therapy in gastrointestinal diseases: in vivo and in vitro approaches.
The first clinical trial in human gene therapy began in 1989 with the successful introduction of marker genes into peripheral blood cells as tumor-infiltrating lymphocytes (TIL) in order to investigate the biological behavior of manipulated cells in humans. In further studies, it was possible to ameliorate clinical genetic diseases based on only one single genetic defect such as adenosine deaminase deficiency (ADA) by repeated infusion of manipulated peripheral blood cells. Meanwhile, a multitude of clinical gene transfer studies were initiated. Three main strategies have thus far been applied in human cancer gene therapy: (1) Reinforcement of the body's immune response by gene transfer into immunological cells; (2) reinforcement of the immune response by manipulating tumor cells; and (3) transfer of drug-sensitive genes into tumor cells with subsequent drug treatment. The first clinical trial in gene therapy for gastrointestinal diseases was performed in 1992 with the introduction of the low-density protein receptor gene (LDL) into liver tissue. Human cancer gene therapy of gastrointestinal diseases is still only in the initial phase of research.
Department of Hematology and Oncology, University Medical Center Benjamin Franklin, Free University of Berlin, Germany.
R
R
Kaiser
E
E
Thiel
E D
ED
Kreuser
D000243:Adenosine Deaminase / Q000172:deficiency; D003110:Colonic Neoplasms / Q000628:therapy; D005767:Gastrointestinal Diseases / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D011973:Receptors, LDL / Q000235:genetics
D011973:Receptors, LDL; D000243:Adenosine Deaminase